DDInter631 DDInter1752
Eltrombopag is used to treat low blood platelet counts in adults with chronic immune (idiopathic) thrombocytopenia (ITP), when certain other medicines, or surgery to remove the spleen, have not worked well enough. ITP is a condition that may cause unusual bruising or bleeding due to an abnormally low number of platelets in the blood. Eltrombopag has also been recently approved (late 2012) for the treatment of thrombocytopenia (low blood platelet counts) in patients with chronic hepatitis C to allow them to initiate and maintain interferon-based therapy.
Drug-resistant bacteria, such as methicillin-resistant _Staphylococcus aureus_, vancomycin-resistant _Enterococcus faecium_, and penicillin-resistant _Streptococcus penumoniae_, represent a massive public health threat.[A199086, A199131] Tedizolid is a member of the oxazolidinone class of antibiotics, which includes the previously approved [linezolid] and is generally effective against multidrug-resistant Gram-positive bacteria. Tedizolid is indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI) and is generally more effective and more tolerable than [linezolid].[L11232, A199086, A199050] Tedizolid was approved by the FDA on June 20, 2014, for sale by Cubist Pharmaceuticals as tedizolid phosphate (SIVEXTRO®). This product is currently available as both an oral tablet and as a powder for intravenous injection.
Eltrombopag {u} (Compound) binds {v} (Gene) CYP2C8
Eltrombopag {u} (Compound) is included by {v} (Pharmacologic Class) Thrombopoietin Receptor Agonists
Eltrombopag {u} may cause a minor interaction that can limit clinical effects when taken with {v} Boceprevir
Eltrombopag {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Idelalisib
Eltrombopag {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Simvastatin
Eltrombopag {u} may lead to a major life threatening interaction when taken with {v} Berotralstat
Eltrombopag {u} may lead to a major life threatening interaction when taken with {v} Peginterferon alfa-2b
Eltrombopag (Compound) binds CYP2C8 (Gene)
Eltrombopag (Compound) is included by Thrombopoietin Receptor Agonists (Pharmacologic Class)
Eltrombopag may cause a minor interaction that can limit clinical effects when taken with Boceprevir
Eltrombopag may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib
Eltrombopag may cause a moderate interaction that could exacerbate diseases when taken with Simvastatin
Eltrombopag may lead to a major life threatening interaction when taken with Berotralstat
Eltrombopag may lead to a major life threatening interaction when taken with Peginterferon alfa-2b